![Page 1: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/1.jpg)
1. US Partner: Competitor or Complementary Player?
2. Single partner for several applications or multiple partners per each?
3. Funding options for research projects?
PCCI January 19, 2009
Diana Mackie, Business Dev. Silvia G Codony, Clinical Research
Contura International A/S(Archive Version)
![Page 2: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/2.jpg)
Contura Business Units
For urinary incontinence
PipelineNew applications of soft tissue
filler technologyFor facial augmentation
Contura is a medical technology company based in Denmark focused on developing, manufacturing and commercializing
soft tissue fillers that enhance the quality of people’s lives
Contura is a medical technology company based in Denmark focused on developing, manufacturing and commercializing
soft tissue fillers that enhance the quality of people’s lives
![Page 3: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/3.jpg)
2000: • Contura established
2001: • Aquamid® granted the CE-marking for use in soft tissue facial augmentation
2003: • Bulkamid® granted the CE-marking for use in the treatment of female urinary
incontinence
2004: • Launch of Aquamid® Reconstruction for lipoatrophy, rhinoplasty and volume
correction
2006: • FDA grants Aquamid® I D E, allowing its use in a major comparative clinical
trial in the United States
2007: • Contura and ETHICON, a J & J company, sign agreement granting ETHICON
exclusive worldwide distribution rights for Bulkamid®.
• Contura’s United States subsidiary Contura Inc. established
• Contura awarded the Product Differentiation Innovation Award for Aquamid® by
Frost & Sullivan
2008: • Clinical trial of Bulkamid® in the United States begins
• New manufacturing facility completed
Contura History and Milestones
![Page 4: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/4.jpg)
Aesthetic Filler Market
Aquamid® Positioning
Aquamid® Pivotal Clinical Trial Results
Partnership Opportunity
![Page 5: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/5.jpg)
US Aesthetics Filler Market
Total Aesthetics Medicine market size exceeds $13 Billion* – Surgical procedures $ 8.4 B
– Non-Surgical procedures $ 4.8 B
Non-Surgical Procedures market size, includes MD fees & product– Botox > $ 1 B
– All soft tissue fillers $ 1 B
Number of Procedures– Botox 4.6 M $350 M at office retail
– Soft Tissue Fillers 1.5 M $350 M at office retail
* Source: Data from 2007 ASAPS and the May 2008 Millenium Research Group Report
![Page 6: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/6.jpg)
Market Dynamics: Many New Introductions
2004 2005 2006 2007 2008 2009
Radiesse Elevess relaunch Restylane Sculptra Juvederm Evolence Artefill (Puragen), Perlane Prevelle___▼_______▼________________▼_▼_▼_▼______▼_▼_▼▼__________►
Sources: industry studies, publications, company information Hyaluronic Acid brands (HAs) , Particle and Polymer brands (PPFs), Collagen brand
![Page 7: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/7.jpg)
After cannibalizing Collagen, HA growth was blunted.
Number of procedures
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2003 2004 2005 2006 2007
Collagen
Auto. Fat
Hyaluronic Acid
Radiesse
Sculptra
Artefill
Source: ASAPS
(ASPS data show same effect)
![Page 8: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/8.jpg)
Competitive PlayersPortfolio Approach in high gear
• Allergan: Botox + very successful launch of Juvederm line
• Mentor: PurTox + Prevelle Silk launch + PLEs (acquired by J&J)
• BioForm: Radiesse + Relaxed Expressions (RF technique alternative to neurotoxin)
• Medicis: Neurotoxin + Restylane line
• Artes Medical: Elevess (HA) + Artefill long duration filler (now in Chapter 7)
Bundling promotions is a key factor for success and is believed to help hold physicians loyal to your line.
![Page 9: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/9.jpg)
Aesthetic Filler Market
Aquamid® Positioning
Aquamid® Pivotal Clinical Trial Results
Partnership Opportunity
![Page 10: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/10.jpg)
US Aesthetics Filler Market
Total Aesthetics Medicine market size exceeds $13 Billion* – Surgical procedures $ 8.4 B
– Non-Surgical procedures $ 4.8 B
Non-Surgical Procedures market size, includes MD fees & product– Botox > $ 1 B
– All soft tissue fillers $ 1 B
Number of Procedures– Botox 4.6 M $350 M at office retail
– Soft Tissue Fillers 1.5 M $350 M at office retail
* Source: Data from 2007 ASAPS and the May 2008 Millenium Research Group Report
![Page 11: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/11.jpg)
Market Dynamics: Many New Introductions
2004 2005 2006 2007 2008 2009
Radiesse Elevess relaunch Restylane Sculptra Juvederm Evolence Artefill (Puragen), Perlane Prevelle___▼_______▼________________▼_▼_▼_▼______▼_▼_▼▼__________►
Sources: industry studies, publications, company information Hyaluronic Acid brands (HAs) , Particle and Polymer brands (PPFs), Collagen brand
![Page 12: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/12.jpg)
After cannibalizing Collagen, HA growth was blunted.
Number of procedures
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2003 2004 2005 2006 2007
Collagen
Auto. Fat
Hyaluronic Acid
Radiesse
Sculptra
Artefill
Source: ASAPS
(ASPS data show same effect)
![Page 13: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/13.jpg)
Competitive PlayersPortfolio Approach in high gear
• Allergan: Botox + very successful launch of Juvederm line
• Mentor: PurTox + Prevelle Silk launch + PLEs (acquired by J&J)
• BioForm: Radiesse + Relaxed Expressions (RF technique alternative to neurotoxin)
• Medicis: Neurotoxin + Restylane line
• Artes Medical: Elevess (HA) + Artefill long duration filler (now in Chapter 7)
Bundling promotions is a key factor for success and is believed to help hold physicians loyal to your line.
![Page 14: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/14.jpg)
Neurotoxin Collagen Hyaluronic Acids
Longer
Lasting
Allergan YES YES YES
Medicis (Pipeline) YES
Mentor +
JnJ
(Pipeline) YES YES
BioForm Relaxed
Expressions
YES
Artes Medical
YES YES
Each company started from one box and has been acquiring to complete the portfolio
![Page 15: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/15.jpg)
Aquamid characteristics:- Non-degradable - Biocompatible, Non-migrational- Non-allergenic, atoxic- Homogeneous (no particles)- Exchanges water, salts and organic molecules with host tissue- Stored without refrigeration
Mode of Action -Volumizer – No intended foreign body reaction -full integration and vascularization
Aquamid Has Unique Properties and Benefits
Aquamid is an injectable hydrogel consisting of 97.5% water and 2.5% cross-linked polyacrylamide (1 ml syringe/27G needle)
![Page 16: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/16.jpg)
Facial skin sags → Surgical Facelift
Loss of subcutaneous fat tissue → volume filler“Boosting volume under the skin”
Wrinkles & folds in lower face → dermal fillers
Lines & wrinkles in upper face → neurotoxins
Ageing
Young
Old
New Trend: Volume Filling and Facial Sculpting
![Page 17: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/17.jpg)
Unique Benefits of Aquamid®
Versatile volumizer: well suited for volumizing and sculpting procedures. Directed to the subcutaneous tissue for immediate filling and lifting effect.
Natural look and feel: The gel is homogeneous. Aquamid® does not induce inflammatory nodules or granulomas. Integrates completely with existing tissue.
Lasting enhancement: non-resorbable and enduring augmentation. Clinical data demonstrate patient and investigator satisfaction that exceeds 90% after 5 years.
![Page 18: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/18.jpg)
Naso labial folds
Lip augmentation
Cheek contouring
Mento labial folds
Glabella filling
Nose correction
Chin augmentation
Scar correction
Facial augmentation to correct lipoatrophy
Minor body contouring
Aquamid® Versatile in Applications
![Page 19: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/19.jpg)
Durability of augmentation
Compatibility with tissue
Evolence
Soft Tissue Filler Positionings
Artefill
Sculptra Radiesse
Juvederm
Restylane
![Page 20: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/20.jpg)
Aquamid® Pivotal US Study Results
Study Design
Results Highlights– Effectiveness– Safety
![Page 21: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/21.jpg)
Study Design
Aquamid® – 210 subjects
Restylane® – 105 subjects
Screening
Treatment to Optimal Max 3 sessions
3M 6M 9M 12M
Treated area: nasolabial folds
13 Sites in the US – each with 19 - 33 subjects
![Page 22: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/22.jpg)
Pivotal Study Key Conclusions
Successfully show that Aquamid® is safe and effective for its intended use.
Support the regulatory requirements for the PMA filing
![Page 23: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/23.jpg)
Market Outlook
Flat to low growth through 1H 2009 due to economy and less DTC advertising for next 6 months – however Botox grew by 13% in a challenging Q4/2008
New aesthetic medicines will launch, about one per year. Premium place given to those that leverage a sales force in place and where bundling can occur
Aquamid® launch in 2010 should find an industry in growth again with receptive physicians and consumers.
![Page 24: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/24.jpg)
Partnership Opportunity
Contura is seeking a US Marketing partner via a US/NA license to commercialize Aquamid® to its target customers.
The framework of a marketing plan is available and shows how Aquamid® would roll out to experienced and trained physicians in soft tissue fillers
Aquamid® will sustain an appropriate price premium.
Supply and further development to come from Contura A/S
![Page 25: 1. US Partner: Competitor or Complementary Player?](https://reader036.vdocument.in/reader036/viewer/2022062614/54667391b4af9fda3f8b4f7b/html5/thumbnails/25.jpg)
Other Potential Partners for Aquamid® Beyond Current Filler Competitors
Therapeutic Dermatology Focus Aesthetic Equipment/Device Focus
Galderma Graceway
American Laser Angiotech Pharma
Merz Nycomed
Cynosure New Star Lasers
Obagi
KIng
PhotoMedex Syneron
SkinMedica Stiefel
Consumer Companies in OTC Derm
Valeant P&G J&J
DermaPlus DermaVance
Schering-Plough Unilever